Human IGFBP-2 Antibody Summary
Glu40-Gln328
Accession # CAA34373
Applications
under non-reducing conditions only
Human IGFBP-2 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IGFBP-2
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Human IGFBP-2 cDNA encodes a 328 amino acid (aa) residue precursor protein with a putative 39 aa residue signal peptide that is processed to generate the 289 aa residue mature protein. IGFBP-2 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. During development, IGFBP-2 is expressed in a number of tissues. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system and in a number of reproductive tissues. IGFBP-2 binds preferentially to IGF II, exhibiting a 2-10 fold higher affinity for IGF‑II than for IGF‑I.
- Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
- Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
Product Datasheets
Citations for Human IGFBP-2 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro
Oncotarget, 2016-05-31;7(22):32129-43.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
Authors: Hu H, Kwun J, Aizenstein BD, Knechtle SJ
Transplantation, 2009-06-27;87(12):1814-20.
Species: Human
Sample Types: Urine
Applications: Antibody Array Development -
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
Biochem. Biophys. Res. Commun., 2005-08-05;333(3):1011-6.
Species: Human
Sample Types: Recombinant Protein
Applications: Western Blot
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IGFBP-2 Antibody
There are currently no reviews for this product. Be the first to review Human IGFBP-2 Antibody and earn rewards!
Have you used Human IGFBP-2 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
